Ginkgo Bioworks to Take “Decisive Action” Following Disappointing Q1 Financial Results

Ginkgo Bioworks, a US-based synthetic biology company, reported disappointing Q1 financial results with total revenue of $38 million, down from $81 million the previous year. The company plans to take "decisive action" to achieve operational breakeven by the end of 2026 by reducing expenditures by $200 million by mid-2025. This includes consolidating facilities, laying off staff, and increasing automation to decrease expenses.

Despite the financial challenges, Ginkgo has had successes in partnerships to produce animal-free dairy proteins and sushi-grade fermented seafood alternatives. The company is working on collaborations to produce fermentation-derived dairy proteins. Ginkgo's CEO, Jason Kelly, expressed disappointment in the Q1 revenues but remains committed to evolving the company to better serve customers and drive revenue growth.